NBIX Stock Neurocrine Biosciences (NBIX, $133.05) RSI Indicator left the overbought zone on December 16, 2024

GET DAILY SIGNALS

Get AI intraday signals

NBIX - Neurocrine Biosciences

RSI signal

View

Odds of DOWN Trend

Price: $133.05

Daily change: +$6.35 (+5.01%)

Daily volume: 1.7M

Capitalization: $13.5B

Industry: Pharmaceuticals: Other

NBIX in downward trend: price may decline as a result of having broken its higher Bollinger Band on December 16, 2024

NBIX broke above its upper Bollinger Band on December 16, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In of the 40 cases the stock fell afterwards. This puts the odds of success at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for NBIX moved out of overbought territory on December 19, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where NBIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 16, 2024. You may want to consider a long position or call options on NBIX as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on December 16, 2024. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

NBIX moved above its 50-day moving average on November 19, 2024 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 263 cases where NBIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.297) is normal, around the industry mean (57.958). P/E Ratio (57.202) is within average values for comparable stocks, (89.727). Projected Growth (PEG Ratio) (0.464) is also within normal values, averaging (2.947). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (19.472).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.